Recent advances in pancreatic cancer detection are offering hope, with new techniques and technologies aiming to identify the ...

Andersson Rolf and her colleagues also found another crucial difference between mouse and human pancreatic development. “We saw the presence of a protein called LGR5, which marks stem cells ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

This opens the door to the development of effective new therapies. Pancreatic cancer ranks among the most lethal cancers, with an exceptionally high mortality rate. One of the reasons is the lack ...

pancreatic cancer represents a common target for pharmaceutical companies. Newer agents are in development with the promise of further refinement in treatment selection based on molecular tumor ...

Our optimized protocol dramatically increased the expression of NKX6.1, leading to an increase in the proportion of PDX1+/NKX6.1+ progenitors (~90%) and upregulation of the key TFs controlling ...

(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

This opens the door to the development of effective new therapies. The work is published in Nature Biomedical Engineering. Pancreatic cancer ranks among the most lethal cancers, with an ...